Treatment of hepatitis C

The combination of pegylated interferon alpha and ribavirin has improved treatment success rates in patients with hepatitis C with sustained response rates of just over 50% overall and more than 70% for those with genotypes 2 and 3. This article reviews the use of combination therapy, contraindicati...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2005-05, Vol.12 (3), p.223-235
Main Authors: Heathcote, J., Main, J.
Format: Article
Language:English
Subjects:
Acute Disease
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Hepacivirus - drug effects
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C virus
Hepatitis C, Chronic - diagnosis
Hepatitis C, Chronic - drug therapy
Humans
Interferon-alpha - therapeutic use
Liver Function Tests
Male
Maximum Tolerated Dose
pegylated interferon alpha
Polyethylene Glycols
Prognosis
Randomized Controlled Trials as Topic
Recombinant Proteins
ribavirin
Ribavirin - adverse effects
Ribavirin - therapeutic use
Risk Assessment
Severity of Illness Index
Treatment Outcome
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The combination of pegylated interferon alpha and ribavirin has improved treatment success rates in patients with hepatitis C with sustained response rates of just over 50% overall and more than 70% for those with genotypes 2 and 3. This article reviews the use of combination therapy, contraindications, factors influencing response and describes approaches to specific patient groups.
ISSN:1352-0504
1365-2893
DOI:10.1111/j.1365-2893.2005.00600.x